Zota Health Care Limited (NSEI: ZOTA)
Health Care · Pharmaceuticals · IN
Rs1,087.40
-3.88% today · -12.1% 1Y
Zota Health Care Limited (NSEI: ZOTA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $393.60M and employs 445 people.
Over the last twelve months the share price has lost 12.1%, trading between 1.03K and 1.74K.
Tweenvest scores Zota Health Care Limited across four factors: quality 60/100, value 59/100, growth 100/100, dividend 3/100. Its strongest factor is growth.
ZOTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $393.60M
- Revenue (TTM)
- $64.38M
- P/E
- —
- EPS
- -30.08
- Dividend yield
- 0.09%
- Beta (5Y)
- 0.42
- 52-week high
- Rs1,740.00
- 52-week low
- Rs1,026.20
- Avg volume (3M)
- —
- Shares outstanding
- 34.63M
- Employees
- 445
- Next earnings
- —
About Zota Health Care Limited
Zota Health Care Limited is an Indian pharmaceutical firm dedicated to the development, manufacturing, and distribution of a broad spectrum of health-related products across India. Its extensive portfolio encompasses generic medications, over-the-counter (OTC) remedies, traditional Ayurvedic formulations, and nutritional supplements (nutraceuticals). The company places a particular emphasis on supplying treatments for various long-term illnesses, including but not limited to heart disease, diabetes, and thyroid conditions. By March 31, 2021, Zota had established a considerable retail network, operating 591 stores under its DAVAINDIA brand name throughout 24 states in India. The company was founded in 1995 and is currently headquartered in Surat, India.
- ISIN
- INE358U01012
- Founded
- 1995
- Listed since
- May 10, 2017
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.